PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT • 2.1 Preface • 2.2 Preface • 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 04: MARKET SIZING • Market definition • Market sizing 2018 • Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 06: MARKET SEGMENTATION BY PRODUCT • Market segmentation by product • Comparison by product • Pain relievers and NSAIDs - Market size and forecast 2018-2023 • Antidepressant and antipsychotic drugs - • Market size and forecast 2018-2023 • Antimicrobial and immunomodulatory drugs - • Market size and forecast 2018-2023 • Market opportunity by product PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE • Geographic segmentation • Geographic comparison • North America - Market size and forecast 2018-2023 • Europe - Market size and forecast 2018-2023 • Asia - Market size and forecast 2018-2023 • ROW - Market size and forecast 2018-2023 • Key leading countries • Market opportunity PART 09: DECISION FRAMEWORK PART 10: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 11: MARKET TRENDS • Development of new diagnostic tests for CFS • R&D of new drugs for the treatment of CFS • Increasing focus on investigation • Role of immune system in CFS PART 12: VENDOR LANDSCAPE • Overview • Landscape disruption PART 13: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • Hemispherx Biopharma, Inc. • Lupin Ltd. • Mylan NV • Pfizer Inc. • Teva Pharmaceutical Industries Ltd. PART 14: APPENDIX • Research methodology • List of abbreviations • Definition of market positioning of vendors PART 15: EXPLORE TECHNAVIO   Exhibit 01: Product overview Exhibit 02: Global pharmaceuticals market Exhibit 03: Segments of global pharmaceuticals market Exhibit 04: Market characteristics Exhibit 05: Market segments Exhibit 06: Market definition - Inclusions and exclusions checklist Exhibit 07: Market size 2018 Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 09: Global market: Year-over-year growth 2019-2023 (%) Exhibit 10: Five forces analysis 2018 Exhibit 11: Five forces analysis 2023 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2018 Exhibit 18: Product - Market share 2018-2023 (%) Exhibit 19: Comparison by product Exhibit 20: Pain relievers and NSAIDs - Market size and forecast 2018-2023 ($ millions) Exhibit 21: Pain relievers and NSAIDs - Year-over-year growth 2019-2023 (%) Exhibit 22: Antidepressant and antipsychotic drugs - Market size and forecast 2018-2023 ($ millions) Exhibit 23: Antidepressant and antipsychotic drugs - Year-over-year growth 2019-2023 (%) Exhibit 24: Antimicrobial and immunomodulatory drugs - Market size and forecast 2018-2023 ($ millions) Exhibit 25: Antimicrobial and immunomodulatory drugs - Year-over-year growth 2019-2023 (%) Exhibit 26: Market opportunity by product Exhibit 27: Customer landscape Exhibit 28: Market share by geography 2018-2023 (%) Exhibit 29: Geographic comparison Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 31: North America - Year-over-year growth 2019-2023 (%) Exhibit 32: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 33: Europe - Year-over-year growth 2019-2023 (%) Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 35: Asia - Year-over-year growth 2019-2023 (%) Exhibit 36: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 37: ROW - Year-over-year growth 2019-2023 (%) Exhibit 38: Key leading countries Exhibit 39: Market opportunity Exhibit 40: Impact of drivers and challenges Exhibit 41: Vendor landscape Exhibit 42: Landscape disruption Exhibit 43: Vendors covered Exhibit 44: Vendor classification Exhibit 45: Market positioning of vendors Exhibit 46: Hemispherx Biopharma Inc. - Vendor overview Exhibit 47: Hemispherx Biopharma Inc. - Business segments Exhibit 48: Hemispherx Biopharma Inc. - Organizational developments Exhibit 49: Hemispherx Biopharma Inc. - Key offerings Exhibit 50: Lupin Ltd. - Vendor overview Exhibit 51: Lupin Ltd. - Business segments Exhibit 52: Lupin Ltd. - Organizational developments Exhibit 53: Lupin Ltd. - Geographic focus Exhibit 54: Lupin Ltd. - Key offerings Exhibit 55: Mylan NV - Vendor overview Exhibit 56: Mylan NV - Product segments Exhibit 57: Mylan NV - Organizational developments Exhibit 58: Mylan NV - Geographic focus Exhibit 59: Mylan NV - Segment focus Exhibit 60: Mylan NV - Key offerings Exhibit 61: Pfizer Inc. - Vendor overview Exhibit 62: Pfizer Inc. - Business segments Exhibit 63: Pfizer Inc. - Organizational developments Exhibit 64: Pfizer Inc. - Geographic focus Exhibit 65: Pfizer Inc. - Segment focus Exhibit 66: Pfizer Inc. - Key offerings Exhibit 67: Teva Pharmaceutical Industries Ltd. - Vendor overview Exhibit 68: Teva Pharmaceutical Industries Ltd. - Business segments Exhibit 69: Teva Pharmaceutical Industries Ltd. - Organizational developments Exhibit 70: Teva Pharmaceutical Industries Ltd. - Segment focus Exhibit 71: Teva Pharmaceutical Industries Ltd. - Key offerings Exhibit 72: Validation techniques employed for market sizing Exhibit 73: Definition of market positioning of vendors

Hemispherx Biopharma Inc., Lupin Ltd., Mylan NV, Pfizer Inc., and Teva Pharmaceutical Industries Ltd.